Innovative Medicine Initiative (IMI) is Europe's largest public-private initiative aiming to speed up the development of better and safer medicines for patients. IMI supports collaborative research projects and builds networks of industrial and academic experts in order to boost pharmaceutical innovation in Europe. IMI is a joint undertaking between the European Union and the pharmaceutical industry association EFPIA.
eTRIKS is a knowledge management and service infrastructure project aimed at development of a software and hardware system capable of the efficient storage and effective analysis of experimental data.
European Autism Interventions - A Multicentre Study for Developing New Medications (EU-AIMS) is a large-scale academic-industry collaboration project to find new methods for the development of drugs for autism spectrum disorder (ASD).
Innovative Medicines Initiative for Diabetes (IMIDIA) is an international research project to improve beta-cell function and identification of diagnostic biomarkers for treatment monitoring in Diabetes.
Mechanism-Based Integrated Systems for the Prediction of Drug-Induced Liver Injury (MIP-DILI) is a collaborative research project. It aims to develop new tests that will help researchers detect potential liver toxicity issues much earlier in drug development, saving many patients from the trauma of liver failure.
d-LIVER is a project funded by the European Union’s 7th Framework Program. The overall goal of the project is to provide safe and cost-effective systems for continuous, context-aware, multi-parametric monitoring of both patient and bio-artificial liver support system parameters in order to: enhance the quality of medical treatment and management; improve the quality of life for patients; reduce the incidence and duration of hospitalization and consequently reduce the health economic burden of chronic liver disease.